Sökresultat - "PD-L1"

Exploration of Bicyclic Peptide Ligands for Immune-Specific PET Imaging: Targeting Tumor PD-L1 with [18F]AlF-BCY10959

Wang, Xiaobo^aff1, Fang, Jianyang^aff2, Kang, Fei^aff1, Wang, Jia^aff1, Niu, Meng^aff1, Ou, Hengyi^aff1, Ye, Jiajun^aff1, Zhang, Mingru^aff1, Dong, Jie^aff3, Li, Guiyu^aff1, Liu, Zhiguo^aff4, Zeng, Wenbin^aff3, Wang, Jing^aff1

Radiosynthesis and Evaluation of a Novel 68Ga-Labeled Peptide for PD-L1-Targeted PET Imaging

Zhang, Fengsheng^{aff1, aff2, aff3, aff4, aff5, aff6, aff7}, Li, Jindian^{aff1, aff2, aff3, aff4, aff5, aff6}, Liu, Xuwei^{aff1, aff2, aff3, aff4, aff5, aff6}, Pan, Xiaoyu^{aff1, aff2, aff3, aff4, aff5, aff6}, He, Simin^{aff1, aff2, aff3, aff4, aff5, aff6}, Zhang, Jianping^{aff1, aff2, aff3, aff4, aff5, aff6}, Shen, Hao^aff7, Tang, Shuang^{aff1, aff2, aff3, aff4, aff5, aff6}, Song, Shaoli^{aff1, aff2, aff3, aff4, aff5, aff6, aff7}

The Detection of Exosomal PD-L1 in Peripheral Blood

Wang, Rui^{Aff4, Aff5, Aff6}, Yang, Yanjia^{Aff4, Aff5, Aff6}, Huang, Jiajun^{Aff5, Aff6}, Yao, Yandan^{Aff4, Aff5, Aff6}

Huang, Tao^Aff1, Yang, Jialiang^Aff2, Tian, Geng^Aff3

Assessment of PD-L1 Status in Urothelial Cancer

Bahlinger, Veronika^Aff6, Hartmann, Arndt^Aff6, Eckstein, Markus^Aff6

Hoffmann, Michèle J.^Aff2, Gaisa, Nadine T.^Aff3, Nawroth, Roman^Aff4, Ecke, Thorsten H.^Aff5, Walker, John M.^Aff1

Highly Efficient Bifunctional Peptides for Tumor Immunotherapy by Simultaneously Activating T Cells and Blocking PD-L1 Immune Checkpoint

Zheng, Aixian^aff1, Wang, Xiaorong^{aff1, aff2}, Wu, Yaning^{aff1, aff2}, Lan, Jing^{aff1, aff2}, Wu, Ming^aff1, Zhang, Da^aff1, Zhang, Fangrong^aff3, Liu, Xiaolong^aff1, Zeng, Yongyi^aff1

Lipid Nanoparticles and PEG: Time Frame of Immune Checkpoint Blockade Can Be Controlled by Adjusting the Rate of Cellular Uptake of Nanoparticles

Choi, Andrew S.^aff1, Moon, Taylor J.^aff1, Bhalotia, Anubhuti^aff1, Rajan, Aarthi^aff1, Ogunnaike, Laolu^aff1, Hutchinson, Diarmuid W.^aff1, Hwang, Inga^aff1, Gokhale, Aaditya^aff1, Kim, Justin N.^aff1, Ma, Timothy^aff1, Karathanasis, Efstathios^{aff1, aff2}

Determining the Multivalent Effects of d‑Peptide-Based Radiotracers

Zhang, Siqi^aff1, Sun, Xiaona^aff1, Liu, Wenhao^aff1, Wu, Jiang^aff3, Wu, Yuxuan^aff1, Jiang, Shuo^aff1, Wang, Xingkai^aff1, Gao, Xin^aff1, Zuo, Quan^aff1, Zhang, Hailong^aff2, Zhang, Yingzi^aff4, Wang, Feng^aff3, Wang, Rui^{aff1, aff2}, Hu, Kuan^aff1

Chimeric Peptide Functionalized Immunostimulant to Orchestrate Photodynamic Immunotherapeutic Effect by PD-L1 Deglycosylation and CD47 Inhibition

Cen, Yi^aff1, Li, Xin-Xuan^aff1, Wang, Min^aff2, Chen, Ying^aff1, Ou, Xiao-Cheng^aff1, Yu, Bai-Xue^aff1, Chen, Xia-Yun^aff1, Wang, Yu-Qing^aff1, Guo, Ning^aff3, Li, Shi-Ying^aff1

Long-term real-world outcomes of first-line immunotherapy in non-small cell lung cancer-a population-based cohort study in Sweden

Wagenius, Gunnar, Vikström, Anders, Berglund, Anders, Salomonsson, Stina, Bencina, Goran, Hu, Xiaohan, Chirovsky, Diana, Brunnstrom, Hans

print

Dual-Synergistic Nanomodulator Alleviates Exosomal PD-L1 Expression Enabling Exhausted Cytotoxic T Lymphocytes Rejuvenation for Potentiated iRFA-Treated Hepatocellular Carcinoma Immunotherapy

Zhu, Xiaoqi^aff1, Li, Tinghua^aff4, Wang, Qin^{aff1, aff3}, Yan, Kangning^{aff1, aff3}, Ma, Shanshan^{aff1, aff3}, Lin, Yuan^{aff2, aff3}, Zeng, Guichun^{aff2, aff3}, Liu, Junjie^aff1, Cao, Jun^aff4, Wang, Duo^aff5

Evaluation of PD-L1, TERT promoter mutations, and BRAFV600E mutation in poorly differentiated, differentiated high grade thyroid carcinoma and anaplastic carcinoma of the thyroid: our institutional experience

Piermattei, Alessia, Migliara, Giuseppe, Feraco, Angela, Bruno, Carmine, Cioni, Luisa, Zhang, Qianqian, Padial-Urtueta, Belen, Merenda, Elisabetta, Fadda, Guido, Raffaelli, Marco, Larocca, Luigi Maria, Mule, Antonino, Pontecorvi, Alfredo, Rossi, Esther Diana^{Aff1, IDs00428025041341_cor1}

An endoplasmic reticulum-targeting photodynamic AMPK agonist activates breast cancer immunotherapy through promoting immunogenic cell death and downregulation of PD-L1

Wu, Ye-yang, Zhang, Ke-yang, Huang, Jia-qi, Nie, Jun-mei, Cheng, Hong^{Aff1, IDs4140102501583x_cor1}

PD-L1 expression correlates with the oncological severity and prognosis of early-stage lung cancer

Onodera, Ken^{Aff1, IDs00595025030706_cor1}, Notsuda, Hirotsugu, Kumata, Sakiko, Watanabe, Tatsuaki, Watanabe, Yui, Suzuki, Takaya, Hirama, Takashi, Oishi, Hisashi, Okada, Yoshinori

Merkel Cell Carcinoma: Current Treatment Landscape and Emerging Therapeutic Targets

Pan, Kelly, Vromans, A. Maria, Cheng, Liang, Grant-Kels, Jane M., Katz, Steven C., Hadfield, Matthew J.^{Aff5, IDs1191202501693z_cor1}

On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC

Szabados, Bernadett E.^{Aff1, Aff2, IDs40487025003346_cor1}, Guerrero-Ramos, Félix, Grande, Enrique, Grivas, Petros, Grünwald, Viktor, Miguel, Marta Carpintero, Hussain, Syed A., Kulkarni, Girish S., Wilson, Ana Lisa, Shore, Neal D.^{Aff9, Aff10}, Sridhar, Srikala S., Hoyt, Mary, Strumeier, Samantha, Sutton, Jennifer, Brinkmann, Julia, Teresi, Rosemary E., Todenhöfer, Tilman

Real-World Maintenance Treatment Patterns Among Patients with Advanced Non-Small Cell Lung Cancer

Shah, Manasee V., Solem, Caitlyn T., Bell, Kelly F., Aziez, Amine, Sun, Xuezheng, Du, Mandy, Du, Ella X., Yang, Hongbo, Wang, Hongjue, Hua, Qi, Tapan, Umit^{Aff6, IDs12325025031788_cor1}

Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation

Zhang, Chenxing, Liu, Jiaxin, Gu, Tiejun, Meng, Xiangyu, Cai, Xiaoyi, Zhang, Jinfeng, Chen, Yan, Zhang, Daguang^{Aff2, IDs10549025076769_cor1}, Wu, Yongge^{Aff1, IDs10549025076769_cor2}

Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China

Wu, Yao, Tao, Libo^{Aff1, Aff2, IDs11096025018658_cor1}, Liu, Chang, Wang, Fangxu, Sun, Shuang

Impact of Doxorubicin and Docetaxel on Immune Checkpoint Expression in Colorectal Cancer: Insights into Chemotherapy Resistance Mechanisms

Ahmadpour Youshanlui, Mahya^Aff1, Nasiri, Hadi^Aff1, Valedkarimi, Zahra, Sadeghi, Mohammadreza, Akbari, Morteza, Motlagh Asghari, Kimia, Jamali, Fereshteh, Abdi, Deniz, Mehramouz, Bahareh, Rasi Bonab, Farnaz, Baradaran, Behzad^{Aff1, Aff3, IDs10528024107964_cor1}

Programmed death-ligand 1 expression in surgically resected thymomas

Frasca, Luca^{Aff1, Aff2}, Sarubbi, Antonio, Longo, Filippo, Marziali, Valentina, Patirelis, Alexandro^{Aff2, Aff3}, Crucitti, Pierfilippo, Ambrogi, Vincenzo^{Aff3, IDs1330402502242w_cor1}